NASDAQ:INMB INmune Bio (INMB) Stock Price, News & Analysis → Your Portfolio’s Shield Against Inflation: Gold’s Surge and AI Breakthroughs (From InvestorPlace) (Ad) Free INMB Stock Alerts $9.92 -0.10 (-1.00%) (As of 05:32 PM ET) Add Compare Share Share Today's Range$9.67▼$10.0950-Day Range$8.37▼$12.8652-Week Range$6.50▼$14.74Volume154,472 shsAverage Volume106,045 shsMarket Capitalization$196.22 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get INmune Bio alerts: Email Address INmune Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside61.3% Upside$16.00 Price TargetShort InterestBearish13.54% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.03Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.96 out of 5 starsMedical Sector797th out of 925 stocksBiological Products, Except Diagnostic Industry135th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingINmune Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageINmune Bio has received no research coverage in the past 90 days.Read more about INmune Bio's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.54% of the float of INmune Bio has been sold short.Short Interest Ratio / Days to CoverINmune Bio has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.Change versus previous monthShort interest in INmune Bio has recently increased by 15.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldINmune Bio does not currently pay a dividend.Dividend GrowthINmune Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INMB. Previous Next 2.2 News and Social Media Coverage News SentimentINmune Bio has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for INmune Bio this week, compared to 2 articles on an average week.Search Interest8 people have searched for INMB on MarketBeat in the last 30 days. MarketBeat Follows2 people have added INmune Bio to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, INmune Bio insiders have not sold or bought any company stock.Percentage Held by Insiders36.10% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.72% of the stock of INmune Bio is held by institutions.Read more about INmune Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of INmune Bio is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of INmune Bio is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioINmune Bio has a P/B Ratio of 4.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about INmune Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceDoes this chart look familiar?Investors who understand when to get in — and when to get out… Can make a lot of money. Like in the chart, I showed you above…Get all the information here. About INmune Bio Stock (NASDAQ:INMB)INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03 develop pre-clinical data in cancer that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Read More INMB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INMB Stock News HeadlinesMay 12 at 5:01 PM | finance.yahoo.comINmune Bio First Quarter 2024 Earnings: EPS Misses ExpectationsMay 11 at 6:15 PM | markets.businessinsider.comRobust Pipeline and Financial Stability Underpin Buy Rating for Inmune BioMay 10 at 6:19 AM | finanznachrichten.deINmune Bio, Inc.: INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business UpdateMay 9, 2024 | globenewswire.comINmune Bio Inc. Announces First Quarter 2024 Results and Provides Business UpdateMay 8, 2024 | americanbankingnews.comINmune Bio (NASDAQ:INMB) Stock Price Down 0.2%May 7, 2024 | finance.yahoo.comINmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9May 1, 2024 | msn.comINmune Bio files for $250M mixed shelf offeringApril 30, 2024 | finance.yahoo.comINmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three YearsApril 30, 2024 | globenewswire.comINmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three YearsApril 29, 2024 | globenewswire.comINmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate CancerApril 26, 2024 | finance.yahoo.comINmune Bio Independent Director Acquires 80% More StockApril 25, 2024 | markets.businessinsider.comInmune Bio Earns Buy Rating on Positive XPro Developments and Strong FinancialsApril 25, 2024 | globenewswire.comINmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 23, 2024 | globenewswire.comINmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity AssayApril 22, 2024 | msn.comINmune Bio rises 2%, on $4.5M direct offeringApril 22, 2024 | finance.yahoo.comINmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingApril 22, 2024 | globenewswire.comINmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingApril 8, 2024 | finance.yahoo.comINmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024April 8, 2024 | globenewswire.comINmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024April 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)April 1, 2024 | finance.yahoo.comINmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call TranscriptMarch 31, 2024 | finance.yahoo.comINmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 30, 2024 | seekingalpha.comINmune Bio, Inc. (INMB) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comINmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical AdvancementsMarch 29, 2024 | finanznachrichten.deINmune Bio, Inc.: INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business UpdateSee More Headlines Receive INMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/13/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:INMB CUSIPN/A CIK1711754 Webwww.inmunebio.com Phone(858) 964-3720FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside+59.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,010,000.00 Net Margins-26,333.59% Pretax Margin-26,333.58% Return on Equity-86.16% Return on Assets-58.41% Debt Debt-to-Equity RatioN/A Current Ratio1.71 Quick Ratio1.71 Sales & Book Value Annual Sales$160,000.00 Price / Sales1,238.72 Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book4.84Miscellaneous Outstanding Shares19,780,000Free Float12,641,000Market Cap$198.20 million OptionableOptionable Beta1.92 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Raymond Joseph Tesi M.D. (Age 68)Co-Founder, President, CEO, Chief Medical Officer & Chairman Comp: $500.5kMr. David J. Moss M.B.A. (Age 54)CFO, Treasurer & Secretary Comp: $394.9kDr. Mark William Lowdell BSc (Age 61)FRCPath, MICR, MSc, Ph.D., Chief Scientific Officer & Chief Manufacturing Officer Comp: $150.24kMr. Joshua S. Schoonover Esq.General CounselKey CompetitorsAcumen PharmaceuticalsNASDAQ:ABOSZura BioNASDAQ:ZURAKodiak SciencesNASDAQ:KODOptheaNASDAQ:OPTInnate PharmaNASDAQ:IPHAView All CompetitorsInsiders & InstitutionsJanney Montgomery Scott LLCSold 22,648 shares on 5/1/2024Ownership: 0.774%Westside Investment Management Inc.Sold 7,475 shares on 4/19/2024Ownership: 0.189%Fermata Advisors LLCBought 2,025 shares on 4/12/2024Ownership: 0.174%Scott JudaBought 7,000 shares on 11/10/2023Total: $48,650.00 ($6.95/share)Timothy J SchroederSold 10,000 sharesTotal: $110,100.00 ($11.01/share)View All Insider TransactionsView All Institutional Transactions INMB Stock Analysis - Frequently Asked Questions Should I buy or sell INmune Bio stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" INMB shares. View INMB analyst ratings or view top-rated stocks. What is INmune Bio's stock price target for 2024? 1 brokers have issued 1-year price targets for INmune Bio's stock. Their INMB share price targets range from $16.00 to $16.00. On average, they expect the company's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 61.3% from the stock's current price. View analysts price targets for INMB or view top-rated stocks among Wall Street analysts. How have INMB shares performed in 2024? INmune Bio's stock was trading at $11.26 on January 1st, 2024. Since then, INMB shares have decreased by 11.9% and is now trading at $9.92. View the best growth stocks for 2024 here. When is INmune Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our INMB earnings forecast. How were INmune Bio's earnings last quarter? INmune Bio, Inc. (NASDAQ:INMB) announced its earnings results on Thursday, May, 9th. The company reported ($0.61) earnings per share (EPS) for the quarter. The firm earned $0.01 million during the quarter. INmune Bio had a negative trailing twelve-month return on equity of 86.16% and a negative net margin of 26,333.59%. What other stocks do shareholders of INmune Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Cidara Therapeutics (CDTX), Gilead Sciences (GILD), Cisco Systems (CSCO), Vaxart (VXRT), Micron Technology (MU), Novavax (NVAX) and SCYNEXIS (SCYX). Who are INmune Bio's major shareholders? INmune Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Janney Montgomery Scott LLC (0.77%), Westside Investment Management Inc. (0.19%) and Fermata Advisors LLC (0.17%). Insiders that own company stock include David J Moss, Mark William Lowdell, Raymond Joseph Tesi, Scott Juda and Timothy J Schroeder. View institutional ownership trends. How do I buy shares of INmune Bio? Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INMB) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldElon’s New Device is About to Shock the WorldInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
